Literature DB >> 3366230

High-dose desferrioxamine as a cause of growth failure in thalassemic patients.

A Piga, L Luzzatto, P Capalbo, S Gambotto, F Tricta, V Gabutti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3366230     DOI： 10.1111/j.1600-0609.1988.tb00198.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  4 in total

1.  Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine).

Authors:  K Sofroniadou; M Drossou; L Foundoulaki; K Konstantopoulos; D Kyriakoy; J Zervas
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 2.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228

Review 3.  Deferoxamine therapy for intracerebral hemorrhage: A systematic review.

Authors:  Liling Zeng; Li Tan; Haijun Li; Qixin Zhang; Yongxian Li; Jianwen Guo
Journal:  PLoS One       Date:  2018-03-22       Impact factor: 3.240

4.  Treating thalassemia major-related iron overload: the role of deferiprone.

Authors:  Vasilios Berdoukas; Kallistheni Farmaki; Susan Carson; John Wood; Thomas Coates
Journal:  J Blood Med       Date:  2012-10-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.